Spotlight Innovation completes Memcine Pharmaceuticals acquisition

Courtesy of

Spotlight Innovation, based in West Des Moines, Iowa, said on Monday that it has completed the acquisition of a majority ownership in Memcine Pharmaceuticals, based at the University of Iowa-Coralville.

Memcine is currently creating a new vaccine platform technology called Immunoplex, which will use the body’s natural defenses as a carrier of vaccine components. This new method will deliver the vaccine to  immune cells to provoke a strong immune response. The new platform is under a license agreement with Memcine and the University of Iowa.

"We are extremely pleased to be moving forward with Memcine Pharmaceuticals' innovative team and technology,” Cris Grunewald, president and CEO of Spotlight Innovation, said. “Memcine Pharmaceuticals' Immunoplex technology has shown enormous potential, with broad applicability in both infectious diseases and oncology immunotherapy. Memcine Pharmaceuticals' mission directly supports Spotlight Innovation's goal of positively impacting the health and well-being of as many people as possible, and we look forward to furthering the development and fulfilling the promise of this exciting, potentially life-saving technology."

"We are excited to be working with Spotlight Innovation to move the Immunoplex platform technology through development and toward clinical use for infectious disease prevention and personalized cancer immunotherapeutics,” Tony Vanden Bush, director and chief scientific officer of Memcine Pharmaceuticals, said.

Organizations in this Story

City of West Des Moines Memcine Pharmaceuticals Spotlight Innovation

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.